
    
      The primary objective of the single rising dose part under fasting and under fed conditions
      is to investigate safety and tolerability of BI 705564 in healthy male subjects following
      oral administration of single rising doses.

      Secondary objectives are the exploration of pharmacokinetics (PK) including dose
      proportionality, and pharmacodynamics (PD) of BI 705564 after single rising doses.

      The objective of the food effect part is to explore the relative bioavailability of BI 705564
      tablets under fed and fasted conditions following the oral administration of single doses.
    
  